Starpharma Receives $7.1m R&D tax incentive refund
- Biopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax incentive refund
- The tax offset relates to SPL’s Australian and global expenses over the 2022 financial year
- The company CEO Jackie Fairley says over the year, the company developed three clinical stage ‘DEP’ assets with “high commercial and therapeutic potential”
- Additionally, SPL developed a portfolio of marketed products, including VIRALEZE, which was registered in its 30th country, Indonesia, earlier this month
- Shares in SPL are up 1.94 per cent to 52.5 cents at 10:58 am AEDT
